



United States Patent [19]

[11] Patent Number: **5,900,403**

Kilbourn et al.

[45] Date of Patent: * **May 4, 1999**

- [54] **USE OF IRON HEMOPROTEIN FOR TREATING PATHOGENIC SYNDROME CAUSED BY NITRIC OXIDE OVERPRODUCTION**
- [75] Inventors: **Robert G. Kilbourn**, Houston, Tex.; **Joseph De Angelo**, Hamtramck, Mich.; **Joseph Bonaventura**, Beaufort, N.C.
- [73] Assignees: **Board of Regents, The University of Texas System**, Austin, Tex.; **Duke University; Apex Bioscience, Inc.**, both of Durham, N.C.
- [*] Notice: This patent is subject to a terminal disclaimer.
- [21] Appl. No.: **08/942,632**
- [22] Filed: **Oct. 2, 1997**

Related U.S. Application Data

- [63] Continuation of application No. 08/184,255, Jan. 18, 1994, Pat. No. 5,674,836, which is a continuation of application No. 07/838,603, Feb. 19, 1992, Pat. No. 5,296,466.
- [51] **Int. Cl.⁶** **A61K 38/42**
- [52] **U.S. Cl.** **514/6; 514/12; 514/21; 530/385; 424/85.2**
- [58] **Field of Search** **514/6, 12, 21; 530/385; 424/85.2**

References Cited

U.S. PATENT DOCUMENTS

4,061,736	12/1977	Morris et al.	424/177
4,584,130	4/1986	Bucci et al.	260/112
4,598,064	7/1986	Walder	514/6
4,751,068	6/1988	Bickar et al.	423/437
5,028,627	7/1991	Kilbourn et al.	514/565
5,082,642	1/1992	Bickar et al.	423/402
5,296,466	3/1994	Kilbourn et al.	514/6
5,334,706	8/1994	Przybelski	530/385
5,480,866	1/1996	Bonaventura et al.	514/6
5,510,464	4/1996	Przybelski	530/385
5,674,836	10/1997	Kilbourn et al.	514/6

FOREIGN PATENT DOCUMENTS

WO 90/02654	7/1990	WIPO .
WO 91/04023	4/1991	WIPO .
WO 91/04024	4/1991	WIPO .
WO 91/84023	4/1991	WIPO .
WO 93/00893	1/1993	WIPO .

OTHER PUBLICATIONS

- Aisaka et al., "N^G-Methylarginine, an Inhibitor of Endothelium-Derived Nitric Oxide Synthesis, is a Potent Pressor Agent in the Guinea Pig: Does Nitric Oxide Regulate Blood Pressure in Vivo?" *Biochemical and Biophysical Research Communications*, 160(2):881-886, 1989.
- Aranow et al., "Effect of Human Hemoglobin on Systemic and Regional Hemodynamics in a Porcine Model of Endotoxemic Shock," *Crit. Care Med.*, 24(9):807-814, 1996.

- Baur, "The Evolution of Methaemalbumin," *Comp. Biochem. Physiol.*, 30:657-664, 1969.
- Bickar et al., "Carbon Monoxide-Driven Reduction of Ferric Heme and Heme Proteins," *Journal of Biological Chemistry*, 259(17):10777-10783, 1984.
- Bone, "A Critical Evaluation of New Agents for the Treatment of Sepsis," *JAMA* 266(12):1686-1691, 1991.
- Bone et al., "Comparison of Different Doses of Pyridoxalated Hemoglobin Polyethylene Conjugate in the Treatment of Hyperdynamic Sepsis," *Society of Critical Care Medicine Conference, New Orleans, Feb. 5-9, 1996*.
- Bone et al., "Effects of Nitric Oxide Scavenging on Sheep Pancreas and Liver During Sepsis," *Experimental Biology '96, Annual meeting of professional Research Scientists, Washington, D.C., Apr. 14-17, 1996*.
- Bone et al., "Hemodynamic Effects of Nitric Oxide Synthase Inhibition and Nitric Oxide Scavenging in Endotoxemic Sheep," *International Anesthesia Research Society, 71st Clinical and Scientific Congress, San Francisco, California, Mar. 14-18, 1997*.
- Bone et al., "Hemodynamic Effects of Pyridoxalated Hemoglobin Polyoxyethylene Conjugate (PHP) in Conscious Sheep During Septic Shock," *American Society of Anesthesiologist, Atlanta, 1995*.
- Bone et al., "Nitric Oxide Synthase Inhibition Versus Nitric Oxide Scavenging in Sepsis," *68th Scientific Sessions of the American Heart Association, Anaheim, California, Nov. 13-16, 1995*.
- Bone, "The Pathogenesis of Sepsis," *Ann. Int. Med.* 115:457-469, 1991.
- Bonkovsky et al., "Intravenous Heme-Albumin in Acute Intermittent Porphyria: Evidence for Repletion of Depaetic Hemoproteins and Regulatory Heme Pools," *The American Journal of Gastroenterology*, 86(8):1050-1056, 1991.
- Brady et al., "Nitric Oxide Production within Cardiac Myocytes Reduces their Contractility in Endotoxemia," *Am. J. Physiol.*, 263 (*Heart Circ. Physiol.* 32):H1963-H1966, 1992.
- Buga et al., "Endothelium-Derived Nitric Oxide Relaxes Nonvascular Smooth Muscle," *European Journal of Pharmacology*, 161:61-72, 1989.
- Chevion et al., "Iron-Nitrosyl Bond configuration in Nitrosyl-Hemoproteins: A Comparative EPR Study of Hemoglobin A and Hemoglobin Kansas," *Israel Journal of Chemistry*, 15:311-317, 1976.

(List continued on next page.)

Primary Examiner—Chhaya D. Sayala
Attorney, Agent, or Firm—Arnold, White & Durkee

[57] ABSTRACT

The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock.

16 Claims, 1 Drawing Sheet